The Women's Tennis Association has introduced a new policy requiring all players to undergo a one-time genetic test to determine their biological sex. This update to the eligibility criteria will involve testing for the SRY gene, which is set to take effect immediately, with potential disciplinary measures for those who refuse to comply.
The previous rules allowed transgender women to participate if they identified as female and maintained low testosterone levels for a period of two years prior to competition. As of now, there are no known transgender women competing at the professional level in tennis. According to the WTA, "the revised policy aims to establish a clear standard for eligibility in WTA events." The association has stated that "eligibility will be verified through a mandatory one-time screening for the SRY gene, with player testing scheduled to commence in 2026, ensuring adherence to strict confidentiality and data protection protocols, alongside a comprehensive engagement program for players." The WTA acknowledges the sensitivity and complexity of this issue and is committed to handling it with respect and dignity for all players. This move follows similar implementations of SRY testing by World Athletics and World Boxing in 2025.